Introduction: The Next Evolution of Weight Loss Has Arrived
The obesity-treatment landscape has changed dramatically over the past few years.
GLP-1 receptor agonists and dual incretin therapies such as semaglutide and tirzepatide have produced levels of weight loss previously achievable only through bariatric surgery. These therapies have helped millions of people lose significant amounts of body weight while improving metabolic health markers and reducing obesity-related complications.
But as clinicians and researchers look deeper into the data, a new question has emerged:
Is all weight loss equally beneficial?
The answer appears to be no.
While GLP-1 therapies can produce substantial reductions in body weight, a portion of that lost weight often comes from lean mass. Lean mass includes skeletal muscle, connective tissue, organs, and body water. Although some lean-mass reduction is expected during any significant weight-loss intervention, preserving skeletal muscle is increasingly viewed as critical for maintaining strength, mobility, metabolic health, and long-term quality of life.
This realization has sparked one of the most exciting areas of obesity research today: combining GLP-1 therapies with myostatin inhibitors.
Researchers hope this strategy can help patients lose more fat while preserving—or potentially improving—muscle mass and overall body composition.
The goal is no longer simply weight loss.
The goal is better weight loss.
Understanding GLP-1 Therapy and Lean Mass Loss
GLP-1 therapies work primarily by influencing appetite regulation, satiety signaling, gastric emptying, and metabolic pathways involved in energy balance.
Popular therapies include:
- Semaglutide
- Tirzepatide
- Emerging dual and triple agonists currently under development
These medications have demonstrated impressive weight-loss outcomes, but body-composition analyses have revealed an important reality:
Not all pounds lost come from fat.
Numerous clinical trials have shown that a percentage of total weight loss may come from lean tissue.
This does not mean GLP-1 therapies are “muscle wasting” drugs.
That narrative oversimplifies the science.
In reality, virtually every successful weight-loss intervention results in some degree of lean-mass reduction. The critical question is whether lean-mass preservation can be improved while maintaining strong fat-loss results.
That challenge has become a major focus for pharmaceutical companies racing to develop the next generation of obesity therapies.
What Is Myostatin?
Myostatin is a naturally occurring protein that regulates muscle growth.
Think of it as one of the body’s built-in brakes.
When myostatin signaling is active, muscle growth is limited. When myostatin activity is reduced or blocked, muscle tissue may be able to grow more readily or resist breakdown.
This concept became famous after researchers discovered rare genetic mutations that dramatically reduced myostatin activity, resulting in unusually high levels of muscularity.
Since then, scientists have spent decades attempting to harness this biology therapeutically.
Myostatin inhibitors are designed to interfere with the signaling pathways that restrict muscle growth.
While initially investigated for muscle-wasting diseases, these therapies are now attracting enormous attention within obesity medicine.
Why Combine Myostatin Inhibitors With GLP-1 Therapies?
The rationale is straightforward.
GLP-1 therapies excel at reducing appetite and promoting weight loss.
Myostatin inhibitors may help preserve muscle during that weight-loss process.
Together, they may produce a more favorable body-composition outcome.
Researchers hope the combination may:
- Increase fat loss relative to lean-mass loss
- Preserve skeletal muscle
- Improve strength and physical function
- Support metabolic health
- Improve long-term weight maintenance
- Reduce frailty risk in older adults
This concept is often referred to as improving the “quality of weight loss.”
Rather than focusing solely on pounds lost, researchers are increasingly focused on what type of tissue is being lost.
The Race to Develop Muscle-Preserving Obesity Therapies
Major pharmaceutical companies have recognized what may be a multibillion-dollar opportunity.
The next obesity blockbuster may not simply be a more powerful appetite suppressant.
Instead, it may be a therapy that helps optimize body composition during weight loss.
Below are the leading therapies currently under investigation.
Leading Myostatin and Muscle-Preservation Therapies
| Therapy | Company | Therapy Type | Development Stage |
|---|---|---|---|
| Bimagrumab | Eli Lilly | Monoclonal Antibody | Phase II/III |
| Apitegromab | Scholar Rock | Monoclonal Antibody | Phase II |
| Trevogrumab | Regeneron | Monoclonal Antibody | Phase II |
| RG-6237 | Roche | Monoclonal Antibody | Phase I |
| Talditercept Alfa | Biohaven | Adnectin Fusion Protein | Phase I |
| EL-22 | NorthStrive Biosciences | Microbiome Therapy | Phase I |
Bimagrumab (Eli Lilly)
Among all muscle-preserving therapies being investigated, Bimagrumab may have one of the longest development histories.
Unlike therapies that specifically target myostatin alone, Bimagrumab blocks activin type II receptors. This broader mechanism potentially influences multiple pathways involved in muscle growth and body composition.
Earlier clinical studies generated substantial excitement after demonstrating reductions in fat mass while simultaneously increasing lean mass.
That combination is particularly attractive in obesity treatment because it suggests the possibility of improving body composition from both directions:
- Less fat
- More lean tissue
Eli Lilly’s acquisition and continued development efforts highlight the growing belief that future obesity treatments will likely involve combinations rather than single-drug solutions.
Researchers are now evaluating whether these body-composition improvements can translate into meaningful real-world benefits such as enhanced mobility, improved metabolic function, and greater long-term health outcomes.
Apitegromab (Scholar Rock)
Apitegromab has rapidly become one of the most discussed compounds in obesity medicine.
Unlike broader pathway inhibitors, Apitegromab selectively targets the activation of myostatin itself.
This selective approach has attracted significant attention because it may offer lean-mass preservation while potentially minimizing unwanted effects associated with broader pathway inhibition.
The therapy gained widespread recognition following Phase II data evaluating its combination with tirzepatide.
Results suggested that individuals receiving Apitegromab alongside tirzepatide retained substantially more lean mass while achieving comparable overall weight loss.
These findings provided one of the strongest proof-of-concept demonstrations that body composition during GLP-1-induced weight loss may be modifiable.
However, important questions remain.
Researchers still need to determine:
- Whether preserved lean mass translates into greater strength
- Whether mobility improves
- Whether long-term outcomes are enhanced
- Which patient populations benefit most
Despite these unanswered questions, Apitegromab is currently viewed by many analysts as one of the most promising therapies in the muscle-preservation category.
Trevogrumab (Regeneron)
Trevogrumab represents Regeneron’s entry into the muscle-preservation obesity market.
The therapy is an anti-myostatin monoclonal antibody currently being evaluated in combination with semaglutide.
Regeneron’s COURAGE trial has become one of the most closely watched obesity studies in the industry.
Early results suggested that Trevogrumab may help preserve lean mass during semaglutide-induced weight loss while potentially improving fat-loss selectivity.
Regeneron has also explored combining Trevogrumab with Garetosmab, an antibody targeting activin A.
The rationale behind this dual-pathway strategy is that broader muscle-preservation effects may produce even greater improvements in body composition.
However, increased biologic complexity often creates additional safety and tolerability considerations.
The ultimate success of Trevogrumab will likely depend on demonstrating that body-composition improvements lead to clinically meaningful functional outcomes while maintaining acceptable safety profiles.
RG-6237 (Roche)
RG-6237 represents Roche’s effort to participate in the rapidly expanding obesity-treatment market.
Although still in early-stage clinical development, the program highlights how seriously large pharmaceutical companies are taking muscle preservation as an emerging therapeutic category.
Publicly available data remain limited due to the program’s early development status.
However, Roche’s investment reflects a growing industry consensus that future obesity therapies may need to address both fat reduction and muscle preservation simultaneously.
As additional data emerge, RG-6237 could become an important player in the next generation of body-composition-focused treatments.
Talditercept Alfa (Biohaven)
Talditercept Alfa introduces a different technological approach.
Rather than utilizing a traditional monoclonal antibody, the therapy employs an adnectin fusion protein platform.
This design may offer unique pharmacologic characteristics compared with conventional antibody-based therapies.
Biohaven is investigating the therapy’s ability to support lean-mass preservation and muscle biology through modulation of myostatin-related pathways.
Although still early in development, Talditercept Alfa demonstrates how innovation within this field extends beyond simply creating additional antibodies.
The diversity of approaches currently under investigation suggests that multiple strategies may eventually compete for leadership in muscle-preservation medicine.
EL-22 (NorthStrive Biosciences)
EL-22 may be the most unconventional therapy in this emerging category.
Unlike direct myostatin inhibitors, EL-22 approaches muscle preservation through microbiome-related mechanisms.
This reflects an increasingly sophisticated understanding of the relationship between gut biology, metabolism, inflammation, body composition, and skeletal muscle.
While still in Phase I development, EL-22 highlights how researchers are expanding beyond traditional muscle-growth pathways in search of novel obesity-treatment solutions.
The success of microbiome-directed approaches could potentially open entirely new therapeutic categories that complement both GLP-1 therapies and muscle-preservation drugs.
Beyond Myostatin: The Emerging Activin Pathway Opportunity
While myostatin receives most of the attention, it represents only one component of a larger signaling network.
Researchers are increasingly studying:
- Activin A
- Activin receptors
- GDF family proteins
- Related muscle-regulating pathways
These targets may ultimately prove equally important in determining muscle preservation during weight loss.
The future obesity-treatment landscape may involve therapies that target multiple biological pathways simultaneously.
Why Body Composition Matters More Than Weight Alone
Historically, obesity treatment focused almost exclusively on scale weight.
That approach may soon become outdated.
A patient who loses 50 pounds primarily from fat may experience a dramatically different outcome than a patient who loses the same 50 pounds but sacrifices substantial muscle mass.
Body composition influences:
- Strength
- Mobility
- Exercise capacity
- Glucose regulation
- Functional independence
- Healthy aging
For this reason, obesity medicine is increasingly shifting toward body recomposition rather than simple weight reduction.
The future may involve routine assessment of:
- Fat mass
- Lean mass
- Muscle quality
- Strength
- Functional performance
rather than focusing solely on body weight.
The Unanswered Questions
Despite tremendous excitement, several critical questions remain unanswered.
Does More Lean Mass Mean Better Function?
This is perhaps the most important question.
Preserving lean mass on a DEXA scan is encouraging.
But patients ultimately care about strength, mobility, energy, and quality of life.
Future studies must demonstrate that body-composition improvements translate into meaningful real-world benefits.
Who Will Benefit Most?
Not every patient may require muscle-preserving therapy.
Potential high-priority populations include:
- Older adults
- Individuals with sarcopenic obesity
- Patients with low baseline muscle mass
- Individuals at elevated frailty risk
Determining ideal patient selection remains a major research priority.
Are Combination Therapies Worth the Cost?
Adding biologics to GLP-1 therapies may significantly increase treatment costs.
Healthcare systems, insurers, and clinicians will demand evidence that benefits justify the additional expense.
What Happens Long-Term?
Long-term durability remains uncertain.
Researchers must determine whether improvements in body composition persist and whether they meaningfully affect long-term health outcomes.
The Future of Obesity Treatment
The obesity therapies of tomorrow may look very different from those available today.
Instead of focusing solely on appetite suppression, future treatment strategies may seek to optimize body composition through multiple mechanisms simultaneously.
A future obesity-management program could include:
- GLP-1 or incretin-based therapy
- Muscle-preservation biologics
- Precision nutrition
- Resistance training
- Digital monitoring tools
- Personalized body-composition assessments
In this model, success would not simply be measured by pounds lost.
It would be measured by improved health, improved function, improved mobility, and improved quality of life.
Final Thoughts
The combination of myostatin inhibitors and GLP-1 therapies represents one of the most exciting developments in obesity medicine.
Early clinical data suggest that preserving lean mass during significant weight loss may be achievable, potentially improving the quality of weight loss rather than simply increasing the quantity.
Companies including Eli Lilly, Scholar Rock, Regeneron, Roche, Biohaven, and NorthStrive Biosciences are now competing to define this emerging therapeutic category.
While substantial questions remain regarding safety, functionality, durability, and patient selection, the direction of the industry is becoming increasingly clear.
The future of obesity treatment may not be about helping people lose more weight.
It may be about helping people lose the right weight.